Home › Brain and Spinal Cord Tumors
Brain and Spinal Cord Tumors clinical trials recruiting in the U.S.
43 studies for Brain and Spinal Cord Tumors are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY10 studies
- Houston, TX9 studies
- Philadelphia, PA7 studies
- Nashville, TN7 studies
- Boston, MA7 studies
- Washington, DC6 studies
- Los Angeles, CA6 studies
- St. Louis, MO5 studies
- Atlanta, GA5 studies
- Ann Arbor, MI5 studies
- Dallas, TX5 studies
- Durham, NC5 studies
- Seattle, WA5 studies
- Columbus, OH5 studies
- Chicago, IL5 studies
- Mountain View, CA5 studies
- Birmingham, AL4 studies
- Memphis, TN4 studies
- Orange, CA4 studies
- San Francisco, CA4 studies
- Miami, FL4 studies
- Kansas City, MO4 studies
- Queens, NY4 studies
- Portland, OR4 studies
- Denver, CO4 studies
- Cincinnati, OH4 studies
- San Antonio, TX4 studies
- New Haven, CT4 studies
- San Diego, CA3 studies
- Hartford, CT3 studies
- Edison, NJ3 studies
- Jacksonville, FL3 studies
- Omaha, NE3 studies
- Baltimore, MD3 studies
- Milwaukee, WI3 studies
- Baldwin Park, CA3 studies
- Fargo, ND3 studies
- Pittsburgh, PA3 studies
- Rochester, MN3 studies
By state
- Alabama4 studies
- Arizona3 studies
- California13 studies
- Colorado5 studies
- Connecticut6 studies
- District of Columbia3 studies
- Florida8 studies
- Georgia5 studies
- Illinois7 studies
- Iowa3 studies
- Kansas3 studies
- Maryland6 studies
- Massachusetts9 studies
- Michigan6 studies
- Minnesota7 studies
- Missouri6 studies
- Nebraska3 studies
- New Jersey4 studies
- New York11 studies
- North Carolina6 studies
- North Dakota3 studies
- Ohio8 studies
- Oregon4 studies
- Pennsylvania9 studies
- Tennessee9 studies
- Texas12 studies
- Virginia4 studies
- Washington6 studies
- Wisconsin4 studies
Recently updated studies
Somatic Mosaicism in Twins Discordant for Childhood Cancer
RecruitingObservational study
Up to age 18 · All sexes · Updated Oct 1, 2026 · NCT06054295Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT07416188Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT04977375PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07827001A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
RecruitingPhase 1
Ages 5 to 18 · All sexes · Updated Sep 15, 2026 · NCT06357377Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04988009Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
RecruitingPhase 2
Ages 10 and older · All sexes · Updated Sep 14, 2026 · NCT03270059Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07098806Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05386108HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Brain Slice Explants to Predict Drug Response in Brain Tumors
RecruitingObservational study
All ages · All sexes · Updated Sep 4, 2026 · NCT05978557A Study of Mirdametinib in People With Central Nervous System Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07539441B7-H3.CD28Z.CART in CNS Neoplasms
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244A Study of PHST001 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Aug 4, 2026 · NCT07680439ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT03922555Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
RecruitingObservational study
All ages · All sexes · Updated Jul 22, 2026 · NCT02530658Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT00991094ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Jun 11, 2026 · NCT04732065From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.